scholarly journals Are Home Buyers Inattentive? Evidence from Capitalization of Energy Costs

2019 ◽  
Vol 11 (2) ◽  
pp. 165-188 ◽  
Author(s):  
Erica Myers
Keyword(s):  
Cost Effectiveness ◽  
Interest Rates ◽  
Energy Cost ◽  
Energy Costs ◽  
Fuel Price ◽  
Mortgage Interest ◽  
Cost Variation ◽  
Wide Range ◽  
Mortgage Interest Rates ◽  
The Cost

This paper explores whether home buyers are attentive to energy costs. The cost-effectiveness of market-based pollution policies crucially depends on whether consumers are attentive to energy costs when purchasing energy-using durables. I exploit energy-cost variation from fuel-price changes in Massachusetts where there is significant overlap in the geographic and age distributions of oil-heated and gas-heated homes. The results strongly reject that home buyers are unresponsive to energy costs under a wide range of consumption and discount-rate assumptions. Furthermore, my preferred specification is consistent with full capitalization of fuel expenditures at discount rates similar to mortgage interest rates. (JEL D14, L71, Q41, Q53, Q58, R31)

scholarly journals Cost-Effectiveness Analysis Comparing Two Approaches for Empirical Antifungal Therapy in Hematological Patients with Persistent Febrile Neutropenia

2013 ◽  
Vol 57 (10) ◽  
pp. 4664-4672 ◽  
Author(s):  
Almudena Martín-Peña ◽  
M. Victoria Gil-Navarro ◽  
Manuela Aguilar-Guisado ◽  
Ildefonso Espigado ◽  
Maite Ruiz Pérez de Pipaón ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Febrile Neutropenia ◽  
Antifungal Therapy ◽  
Standard Approach ◽  
Sensitivity Analyses ◽  
Treatment Pathways ◽  
Hematological Patients ◽  
Wide Range ◽  
Empirical Antifungal Therapy ◽  
The Cost

ABSTRACTNew approaches of empirical antifungal therapy (EAT) in selected hematological patients with persistent febrile neutropenia (PFN) have been proposed in recent years, but their cost-effectiveness has not been studied. The aim of this study was to compare the cost-effectiveness of two different approaches of EAT in hematological patients with PFN: the diagnosis-driven antifungal therapy (DDAT) approach versus the standard approach of EAT. A decision tree to assess the cost-effectiveness of both approaches was developed. Outcome probabilities and treatment pathways were extrapolated from two studies: a prospective cohort study following the DDAT approach and a randomized clinical trial following the standard approach. Uncertainty was undertaken through sensitivity analyses and Monte Carlo simulation. The average effectiveness and economic advantages in the DDAT approach compared to the standard approach were 2.6% and €5,879 (33%) per PFN episode, respectively. The DDAT was the dominant approach in the 99.5% of the simulations performed with average cost-effectiveness per PFN episode of €32,671 versus €52,479 in the EAT approach. The results were robust over a wide range of variables. The DDAT approach is more cost-effective than the EAT approach in the management of PFN in hematological patients.

4.4 A Policy for Encouraging the Effective Use of Computers in Animal Production Development

1981 ◽  
Vol 5 ◽  
pp. 137-140
Author(s):  
C. T. Whittemore
Keyword(s):  
Cost Effectiveness ◽  
Real Life ◽  
Simulation Models ◽  
Agricultural Industry ◽  
Flat Rate ◽  
Wide Range ◽  
Business Forecasting ◽  
Development Workers ◽  
Effective Use ◽  
The Cost

In addition to data and record handling and the completion of complex and arduous mathematical calculations, the computer may serve a wide range of purposes for the agricultural industry; these include the provision of day-to-day management information, the mechanical enactment of management decisions, business forecasting, interpretation of real life and prediction of future response by use of simulation models, analysis of cost effectiveness of various tactics and stratagems, the transfer of information, scrutinization of existing knowledge and the formulation of experimental programmes. The computer is seen as a major linking medium between research, development and production practice; being both the preferred route for information flow and an ideal way of packaging dispersed pieces of knowledge into practical, usable, systems advice.The concern of practical producers is not with discrete little problems but with systems. To help, the extension worker must bring forward systems solutions. Often research and development workers try to get across to producers potential benefits in small bits (3 times daily milking gives a yield lift of 15%; flat rate feeding gives better margins over concentrates; high density diets improve feed efficiency), whereas producer benefits come from the cost effectiveness of whole integrated systems.

scholarly journals The cost-effectiveness of hypertension management in low-income and middle-income countries: a review

2020 ◽  
Vol 5 (9) ◽  
pp. e002213
Author(s):  
Deliana Kostova ◽  
Garrison Spencer ◽  
Andrew E Moran ◽  
Laura K Cobb ◽  
Muhammad Jami Husain ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Low Income ◽  
Disease Risk ◽  
National Income ◽  
Economic Evaluations ◽  
Health Improvement ◽  
Middle Income ◽  
Middle Income Countries ◽  
Wide Range ◽  
The Cost

Hypertension in low-income and middle-income countries (LMICs) is largely undiagnosed and uncontrolled, representing an untapped opportunity for public health improvement. Implementation of hypertension control strategies in low-resource settings depends in large part on cost considerations. However, evidence on the cost-effectiveness of hypertension interventions in LMICs is varied across geographical, clinical and evaluation contexts. We conducted a comprehensive search for published economic evaluations of hypertension treatment programmes in LMICs. The search identified 71 articles assessing a wide range of hypertension intervention designs and cost components, of which 42 studies across 15 countries reported estimates of cost-effectiveness. Although comparability of results was limited due to heterogeneity in the interventions assessed, populations studied, costs and study quality score, most interventions that reported cost per averted disability-adjusted life-year (DALY) were cost-effective, with costs per averted DALY not exceeding national income thresholds. Programme elements that may reduce cost-effectiveness included screening for hypertension at younger ages, addressing prehypertension, or treating patients at lower cardiovascular disease risk. Cost-effectiveness analysis could provide the evidence base to guide the initiation and development of hypertension programmes.

Racial Discrepancy in Mortgage Interest Rates

2014 ◽  
Vol 51 (1) ◽  
pp. 101-120 ◽  
Author(s):  
Ping Cheng ◽  
Zhenguo Lin ◽  
Yingchun Liu
Keyword(s):  
Interest Rates ◽  
Mortgage Interest ◽  
Mortgage Interest Rates

scholarly journals The Feasibility of Lowering Energy Costs Through Reduced Delivery Frequency

1980 ◽  
Vol 9 (1) ◽  
pp. 13-15
Author(s):  
James G. Beierlein ◽  
Robert J. Campbell
Keyword(s):  
Net Present Value ◽  
Energy Savings ◽  
Transportation Costs ◽  
Energy Costs ◽  
Present Value ◽  
Fuel Price ◽  
Fuel Prices ◽  
Price Increases ◽  
Net Revenue ◽  
The Cost

The feasibility of reducing delivery frequency as a means of lowering energy and transportation costs is examined. Four reduced delivery situations are examined using a net present value criteria. While substantial energy savings are possible the cost of equipment necessary to accommodate these reductions outweighs the energy savings at current fuel prices. Substantial fuel price increases are required before such reductions are worthwhile. Good management requires examination of the net effect of energy savings on net revenue.

Cost-effectiveness of targeting chemotherapy with the 70-gene prognostic signature in early-stage breast cancer (ESBC) patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6570-6570
Author(s):  
K. B. Tong ◽  
E. Chen ◽  
G. Brink ◽  
R. Bender ◽  
F. de Snoo ◽  
...  
Keyword(s):  
Lymph Node ◽  
Cost Effectiveness ◽  
Adjuvant Chemotherapy ◽  
Cost Effective ◽  
Gene Signature ◽  
Risk Classification ◽  
Node Negative ◽  
Life Years ◽  
Wide Range ◽  
The Cost

6570 Background: The 70-gene microarray test (MammaPrint) has been shown to provide additional prognostic information to clinicopathologic risk assessment for women ESBC; however, the cost-effectiveness of this strategy is not well understood. Methods: The objective of this analysis was to estimate the incremental benefits, costs, and cost-effectiveness of the treatments guided by the 70-gene signature versus Adjuvant! Software (AS) to decide on the use of adjuvant chemotherapy for women ≤61 years with lymph node negative, HER-2 negative ESBC with estrogen receptor (ER) positive or negative disease. A Markov model with a lifetime horizon and three health states (alive without recurrence, death from cancer and death from other causes) was constructed using TreeAge Pro software. Risk classification and patient outcomes data were based on a multi-center 70-gene signature validation study. Efficacy of chemotherapy derived from published meta-analysis of clinical trials. Costs and health utilities were obtained from the literature. Costs and benefits were discounted 3%/year. Results: Compared to AS, the 70-gene signature strategy resulted in 35% of patients being reassigned to a different risk classification and avoided chemotherapy in 9% of patients. In the base case, the 70-gene signature strategy was cost neutral (lifetime costs per patient: $178,811 versus $178,893 for the 70-gene signature and AS strategy). Moreover the 70-gene signature strategy was associated with an increase of 0.13 life years (LYs) and 0.16 quality adjusted life years (QALYs). The model results were sensitive to the cost of 70-gene signature test, cost of adjuvant chemotherapy, and relative risk reduction associated with chemotherapy; however, the 70-gene strategy remained cost-effective across a wide range of assumptions. Conclusions: In this analysis, the 70-gene signature was associated with a reduction in chemotherapy use and an increase in life expectancy. The 70-gene signature appears to be a cost-effective strategy for obtaining additional information to guide the decision to use adjuvant chemotherapy in patients with lymph node negative ESBC. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document